← Back to Search

Carbapenem

Piperacillin/Tazobactam vs Meropenem for Bacterial Blood Infections (PETERPEN Trial)

Phase 4
Recruiting
Led By Roni Bitterman, MD
Research Sponsored by Rambam Health Care Campus
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
The microorganism will have to be non-susceptible to third generation cephalosporins (ceftriaxone and ceftazidime) and susceptible to both PTZ and meropenem (see microbiological methods)
We will permit the inclusion of bacteremias due to E. coli or Klebsiella spp. with concomitant growth in blood of skin commensals considered as contaminants
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 30 days and 90 days from randomization
Awards & highlights

PETERPEN Trial Summary

This trial is testing whether piperacillin-tazobactam is as good as meropenem for treating blood-stream infections caused by bacteria that are resistant to cephalosporins.

Who is the study for?
Adults over 18 with bloodstream infections caused by specific bacteria (E. coli or Klebsiella spp.) resistant to certain antibiotics but susceptible to Piperacillin/tazobactam and Meropenem can join. Excluded are those with septic shock, polymicrobial bacteremia, certain severe infections like endocarditis, allergies to study drugs, previous trial participation, or other clinical trials.Check my eligibility
What is being tested?
The PETERPEN trial is testing whether Piperacillin/tazobactam is as effective as Meropenem in treating bloodstream infections from cephalosporin-resistant Enterobacteriaceae. It's a head-to-head comparison of these two antibiotic treatments.See study design
What are the potential side effects?
Possible side effects include allergic reactions, gastrointestinal issues like nausea and diarrhea, headache, skin rash or itching. Both antibiotics may also affect liver enzymes and white blood cell counts.

PETERPEN Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
The infection I have is resistant to certain antibiotics but can be treated with PTZ and meropenem.
Select...
I have a blood infection caused by E. coli or Klebsiella, possibly with other non-harmful bacteria.
Select...
I am 18 years old or older.
Select...
I have a blood infection, whether caught at home or in the hospital.
Select...
I have a new blood infection caused by E. coli or Klebsiella.

PETERPEN Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~30 days and 90 days from randomization
This trial's timeline: 3 weeks for screening, Varies for treatment, and 30 days and 90 days from randomization for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Secondary outcome measures
Adverse events
All-cause mortality
Carriage of carbapenemase-producing Enterobacteriaceae (CPE) and non-CPE carbapenem-resistant Enterobacteriaceae in-hospital
+9 more

PETERPEN Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: piperacillin tazobactamExperimental Treatment1 Intervention
Group II: meropenemActive Control1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Piperacillin
FDA approved

Find a Location

Who is running the clinical trial?

McGill University Health Centre/Research Institute of the McGill University Health CentreOTHER
442 Previous Clinical Trials
158,090 Total Patients Enrolled
Meir Medical CenterOTHER
398 Previous Clinical Trials
85,639 Total Patients Enrolled
University of Modena and Reggio EmiliaOTHER
89 Previous Clinical Trials
31,569 Total Patients Enrolled

Media Library

Meropenem (Carbapenem) Clinical Trial Eligibility Overview. Trial Name: NCT03671967 — Phase 4
Meropenem (Carbapenem) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03671967 — Phase 4

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the sample size of this medical experiment?

"Affirmative. As per the information hosted on clinicaltrials.gov, this research is actively recruiting participants; it was launched May 1st 2019 and has been amended for the last time as of July 25th 2022. The study necessitates 1084 patients across a single site."

Answered by AI

To what extent can Piperacillin/tazobactam be relied upon for patient safety?

"Having already been approved, the safety of Piperacillin/tazobactam is rated highly and given a score of 3."

Answered by AI

Is registration for this clinical trial currently available to patients?

"The information found on clinicaltrials.gov demonstrates that this trial is actively enrolling patients as of now. This programme was initially posted in May 2019 and revised most recently in July 2022."

Answered by AI
~271 spots leftby Jan 2026